Faeth Therapeutics, Inc.
NASDAQFaeth Therapeutics sits at the intersection of unusually strong Street consensus and a short position that has now grown beyond the entire freely traded float — a combination that rarely resolves quietly. The short-side dynamics remain the most urgent story, and they have shifted further since the note published earlier today. Short interest confirmed at 124% of free float on…
FTH short interest surges to 76.8% of float, up 49.5% in one week as cost to borrow falls to 112.7%.
Faeth Therapeutics sits at the intersection of unusually strong Street consensus and a short position that has now grown beyond the entire freely traded float — a combination that rarely resolves quietly. The…
Faeth Therapeutics is navigating a striking divergence: eleven analysts have initiated with Buy ratings and targets as high as $70, yet short interest has nearly doubled in a month and now exceeds the entire free…
Snapshot as of 26 Sept 2026
Faeth Therapeutics is at the centre of a striking divergence this week: short sellers are rapidly covering a historically extreme position while the company's own CFO is stepping in to buy shares on the open…
Sensei Biotherapeutics heads into its May 22 earnings call in one of the most extreme short-side configurations available in the market today. The borrow market is comprehensively seized up. Short interest has reached…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for FTH — free to start on ORTEX.
Sign up for free →Open FTH on ORTEX